ANKRD20A17P

Across TCGA pan-cancer cohorts, ANKRD20A17P RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of ANKRD20A17P’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where ANKRD20A17P RNA is repressed in tumor relative to normal tissue. In most cancer types ANKRD20A17P is over-expressed in tumor, although a few such as LUSC and LUAD show the opposite, repressed pattern.

LUSC, LUAD, and BRCA are the cancer types where ANKRD20A17P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKRD20A17P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	All	All	−0.176	<.001	7	view →
LUAD	Female	II,III,IV	−0.210	<.001	6	view →
BRCA	All	III,IV	−0.181	<.001	6	view →
THCA	All	All	−0.036	<.001	3	view →
PRAD	All	All	+0.191	.001	2	view →
LIHC	All	All	+0.154	.006	2	view →
UCEC	All	All	−0.033	.042	2	view →
COAD	Female	All	−0.019	.022	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

ANKRD20A17P–LUSC

Open the LUSC breakdown →